In recent years, we found key molecular drivers on treatments were targeted NAFLD, including regulating carbohydrate-responsive element-binding protein (ChREBP) to inhibit obesity and insulin-resistant ob/ob mice to reverse hepatic steatosis. Here, INS is linked to fatty liver disease.